Outcomes and cost-effectiveness of gamma knife radiosurgery and whole brain radiotherapy for multiple metastatic brain tumors.

We aimed to analyze the outcomes and cost-effectiveness of gamma knife radiosurgery (GKRS) and whole brain radiotherapy (WBRT) for multiple metastatic brain tumors. Over a period of 5 years, 156 patients with multiple metastatic brain tumors were enrolled and freely assigned by the referring doctors to either gamma knife radiosurgery (GKRS, Group A, n=56), or to whole brain radiotherapy (WBRT, Group B, n=100). The follow-up time was set at 1200 days (3.3 years) post-treatment. The number of tumors, patient age, extent of systemic disease and Karnofsky performance scale (KPS) score, were recorded and recursive partitioning analysis used. The outcomes analyzed were: mortality, survival time, neurological complications, post-treatment KPS score, quality-adjusted life years (QALY), and cost-effectiveness. A paired t-test was used for statistical analysis. Mortality rates for patients receiving GKRS and WBRT were 81.1% and 93.0%, respectively (p=0.05). The mortality rate was lower for GKRS (74.4%) than for WBRT (97.1%) in patients with initial KPS70 (p=0.02). The mortality rate was also significantly lower for GKRS (78.9%) than WBRT (95.5%) in patients with 2-5 tumors (p<0.05). Post-treatment KPS score (mean+/-standard deviation [s.d.] was higher for patients receiving GKRS (73.8+/-13.2) than for those receiving WBRT (45.5+/-26.0), p<0.01. The median survival time for GKRS and WBRT was 9.5 months and 8.3 months, respectively, p=0.72. The mean (+/- s.d.) QALY was 0.76+/-0.23 for GKRS and 0.59+/-0.18 for WBRT, respectively (p<0.05). The cost-effectiveness per unit of QALY was better for the GKRS treatment (US$10,381/QALY) than in the WBRT treatment (US$17,622/QALY), p<0.05. The cost-effectiveness per KPS score was also higher for the GKRS treatment (US$139/KPS score) than for WBRT (US$229/KPS score), p<0.01. Thus, the mortality rate for multiple metastatic brain tumors treated by GKRS is significantly better with a good initial KPS score and when the tumor number is 2-5. GKRS results in a better post-treatment KPS score, QALY, and higher cost-effectiveness than WBRT for treating multiple metastatic brain tumors.

A new Modified Intracerebral Hemorrhage score for treatment decisions in basal ganglia hemorrhage--a randomized trial.

OBJECTIVES: To develop a Modified Intracerebral Hemorrhage (MICH) score to determine optimal cut-offs for conservative treatment vs surgical intervention for basal ganglia hemorrhage and to predict outcomes. DESIGN: Prospective randomized trial. SETTING: A 1,720-bed medical center affiliated with a university. PATIENTS: In all, 226 patients with basal ganglia hemorrhage who presented at our hospital from 2001-2005. INTERVENTIONS: Group A (n = 113) underwent endoscopic surgery; group B (n = 113) underwent conservative treatment. Score differences on the Glasgow Outcome Scale and 1-yr Barthel Index were analyzed by chi-square test and Student's t-tests. Cut-offs for MICH scoring were evaluated using receiver operating characteristic curves for calculating the Youden Index. The treatment odds ratio was analyzed by univariate, multivariate, and multiple logistic regressions. MEASUREMENTS AND MAIN RESULTS: The optimal cut-off point for mortality was a MICH score > or = 3 in which the Youden Index is 0.66 (sensitivity, 76.3%; specificity, 89.8%; area under the receiver operating characteristic curve, 0.897). The positive and negative predictive values were 81.8% and 86.3%, respectively. The treatment odds ratio for surgical treatment was 6.87 (95% confidence interval, 3.13-14.5) at MICH scores > or = 3. The best cut-off for good functional outcomes (Glasgow Outcome Scale > or = 4 or Barthel index > or = 55) was MICH > or = 2. Conservative treatment achieved a better mean Barthel Index at MICH = 0 or 1 than surgical treatment, p < .01. At MICH scores = 3 or 4, 6-month mortality for conservative treatment was higher than for surgical treatment, p < .01 and p = .04, respectively. At MICH scores of 5, all patients died. CONCLUSIONS: MICH scoring provides a simple, reliable system for treatment decisions regarding basal ganglia hemorrhage and may accurately predict functional outcomes. Conservative treatment is recommended for basal ganglia ICH patients with low MICH scores (0, 1) to preserve neurologic function. Surgery is recommended for patients with a midlevel MICH score to obtain better functional outcomes (MICH = 2) and to reduce mortality (MICH = 3 or 4). At MICH scores = 5, there are no indications for surgery.